NCT05132790 - Breast Cancer Study of Stereotactic Body Radiation Therapy (SBRT) Combined Neoadjuvant Treatment | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 25, 2023

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2028

Conditions

Breast Cancer

Interventions

DRUG

SHR-1316 at a dose 20mg/kg q3w

Combination of SBRT and SHR1316, followed by SHR1316 plus nab-paclitaxel and carboplatin or cisplatin

DRUG

SHR6390 at a dose of 150mg orally, daily

SHR6390 plus exemestane with/without ovarian function suppression/ablation (OFS) after SBRT

RADIATION

SBRT

radiation therapy for breast cance before surgery.

Trial Locations (1)

Shengjing Hospital of China Medical University, Shenyang

All Listed Sponsors

collaborator

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

lead

Shengjing Hospital

OTHER